Genzyme Corporate Research Search Genzyme Websites
Gaucher Disease Treatment Information for Parents and FamiliesGaucher Disease Treatment Information for Health Care Providers
Return to Home Page


Search

Health Care Professionals
Disease Information
About Cerezyme
Safety
Disease Management
Rationale
Comprehensive Assessment
Therapeutic Goals
Dosing
Regular Monitoring
Getting to Goal
Safety Information
Disease Management Materials
Ordering & Billing
Resources & Support
Prescribing Information (PDF)

Comprehensive Assessment


Regardless of clinical presentation and symptoms, all patients should receive an initial comprehensive assessment of all potential disease compartments: anemia, thrombocytopenia, hepatomegaly, splenomegaly, skeletal pathology, growth retardation in pediatric patients, pulmonary involvement, functional health and well-being, and a thorough physical examination. The information obtained should then be used to establish therapeutic goals for all disease compartments. The recommended primary assessments are:

Physical examination
Hematologic
(hemoglobin and platelet count)
Biochemical
(chitotriosidase, angiotensin-converting enzyme, and/or tartrate-resistant acid phosphatase)
Visceral
(liver and spleen volumes)
Skeletal
(assessment of bone marrow infiltration, osteonecrosis, and osteopenia)
Patient-reported Quality-of-Life

Important Safety Information

Adverse reactions related to Cerezyme® (imiglucerase for injection) administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Symptoms suggestive of hypersensitivity include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension. Approximately 15% of patients have developed IgG antibodies; periodic monitoring is suggested. Side effects should be reported promptly to Genzyme Medical Information at 800-745-4447, option 2. To learn more, please see full product information (PDF), or contact Genzyme at 1-800-745-4447.


Highlights
Did You Know...
Gaucher disease is an autosomal recessive disorder defined by the presence of two mutant alleles for the glucocerebrosidase gene.

Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142

800-745-4447
617-768-9000

Contact Genzyme